MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy
- 31 January 2008
- journal article
- research article
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 198 (1), 99.e1-99.e7
- https://doi.org/10.1016/j.ajog.2007.05.019
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Concomitant chemotherapy and radiation therapy for cancer of the uterine cervixCochrane Database of Systematic Reviews, 2005
- Cancer/testis antigens, gametogenesis and cancerNature Reviews Cancer, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcriptionNucleic Acids Research, 2004
- Carcinoma of the cervix uteriInternational Journal of Gynecology & Obstetrics, 2003
- Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervixGynecologic Oncology, 2003
- Tissue Microarray Evaluation of Melanoma Antigen E (MAGE) Tumor-Associated Antigen ExpressionAnnals of Surgery, 2002
- Cancer Tumor antigensCurrent Opinion in Immunology, 1997
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997
- Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.The Journal of Experimental Medicine, 1994